Latest
Kat Zilka Builds Dis//Connect Around Teen Screen Time, As Grassroots Phone Interventions Outrun Policy
International Fertility Group Halts MRT Program After Scrutiny Of Age-Related Infertility Claims
Synchron Pauses Second-Generation Brain-Computer Interface Trial, Delaying FDA Submission
Across the beats
- AI in Drug Discovery
Valo And Montai Merge Under Valo Brand, Putting MTAI-1025 At The Front Of The Pipeline
The Catalyst Brief Nov 12, 2026 - Biopharmaceutical Industry
Arrowhead Defends Redemplo’s SHTG Launch Setup After Ionis Reports $9 Million Tryngolza Sales
The Catalyst Brief Nov 14, 2026 - Biotech Innovation
Rezolute Posts Phase 3 Ersodetug Win In Tumor Hyperinsulinism, Ahead Of FDA Congenital HI Talks
The Catalyst Brief Nov 13, 2026 - Healthcare Investment
Windward Bio Prices $175 Million IPO, Pushing 2026 Biotech Debuts To 35
The Catalyst Brief Nov 14, 2026 - Medical Technology
American Cancer Society Revises PSA Screening Guidance, Recommending Biennial Testing From Age 50
The Catalyst Brief Nov 12, 2026 - Regulatory & Policy
American Society Of Addiction Medicine Issues First National Medetomidine Withdrawal Guidance, As ICU-Level Cases Spread
The Catalyst Brief Nov 14, 2026
Most read

Abbott Wins FDA Approval And CE Mark For UltiSynq Lead, Adding A Dual-Purpose ICD Option

Summit, Capricor, And Vertex Face November FDA Calls, With Ivonescimab, Deramiocel, And Povetacicept In Focus

Merck Abandons MK-1484, Extending Its Retreat From IL-2 After Sutro Partnership

Novartis Confirms 9 Tumor Reports In Zolgensma-Treated Patients, With 2 Showing Vector Integration Evidence
More coverage
Biopharmaceutical IndustryPharmaLogic Buys Lantheus Plant, Extending Its Radiopharmaceutical CDMO Reach Across The Atlantic
The assets came to Lantheus through its $250 million upfront acquisition of Evergreen Theragnostics last year, but are now being sold 19 months later. For PharmaLogic, the purchase adds a 14,000-square-foot facility with seven commercial-scale production suites and strengthens its claim to a transatlantic therapeutic CDMO platform.
Biopharmaceutical IndustryCharles River Buys Two Frontage Labs For $470 Million, Expanding Clinical Bioanalysis Capacity
The acquisition gives Charles River two Exton, Pennsylvania sites totaling 150,000 square feet and around 340 employees. For the CRO, the transaction is less about adding lab space than about tightening the handoff between preclinical and clinical testing as biologics and more complex modalities take a larger share of pipelines.
Healthcare InvestmentWindward Bio Hits $225 Million IPO Goal, Funding China-Licensed Respiratory Programs
The Basel-based biotech sold 10.3 million shares at $17 apiece and could add around $26.2 million more if underwriters exercise their option for another 1.5 million shares. The raise is aimed primarily at WIN378 in COPD and asthma, with additional capital earmarked for the dual-targeting WIN027 and earlier bispecific work.
Biotech InnovationRegeneron Posts Positive Phase 2 Baloncibart Data In POTS, Setting Up A 2027 Phase 3 Trial
In the 82-patient Pinnacle study, a single 450 mg dose reduced the change in heart rate from lying down to standing by 11.4 beats per minute versus placebo at Day 8 and by 7.4 beats per minute at Day 29. The signal was weaker at 150 mg, while adverse events were more common on treatment but were mostly mild or moderate and did not lead to discontinuations.
Biopharmaceutical IndustryBristol Myers Squibb Reorganizes R&D, With Robert Plenge Departing Amid Patent-Loss Pressure
Bristol Myers Squibb said its R&D reorganization is meant to connect scientific and clinical expertise more closely and sharpen portfolio execution. Chief Research Officer Robert Plenge will leave by the end of the year, while Cristian Massacesi will take charge of the unified organization at the start of next year.
Biotech InnovationKyverna Halts KYV-102 To Focus On Miv-Cel, Narrowing Its Autoimmune CAR-T Bet Ahead Of FDA Review
KYV-102 had been positioned as a way to expand access and reduce costs by using Kyverna’s whole-blood, rapid manufacturing process and avoiding apheresis. The company now says it will pursue those long-term goals through lifecycle management and by building on the later-stage miv-cel program.
Biopharmaceutical IndustryVor Pays RemeGen $10 Million Upfront For RC298, Extending BAFF/APRIL Autoimmune Bet
The transaction shows Vor is building depth around one autoimmune mechanism rather than broadening into unrelated assets. It also suggests the company sees dosing convenience as a commercial and clinical differentiator worth buying before human data are available outside the existing franchise context.
Regulatory & PolicyARPA-H Backs Ibogaine With Up To $4.9 Million, Expanding Federal Psychedelic Focus Beyond Psilocybin
The funding announcement signals a broader government effort to test multiple psychotropic approaches rather than rely on a single development path. It also places ibogaine, a substance with a more unconventional clinical profile than better-known psychedelic candidates, inside a federal program aimed at generating IND-ready evidence across more than one indication.
Regulatory & PolicyFDA Appears To Pause CNPV Reviews And CRL Disclosures, Leaving Makary-Era Reforms In Limbo
Reuters, as cited by Fierce Biotech, reported that the FDA has quietly shelved the Commissioner’s National Priority Voucher pilot for new awards, even as the agency says work under the program is ongoing for applications that already received a voucher. At the same time, the FDA has not added a new complete response letter to its public database for the past three months, despite saying it remains committed to publishing appropriately redacted letters.
Healthcare InvestmentNeurosterix Raises $105 Million Series B, Funding A Planned Phase 2 Schizophrenia Trial
Addex Therapeutics’ neuropsychiatric spinout said the new financing will primarily support NTX-253, an oral muscarinic M4 positive allosteric modulator being prepared for phase 2 in schizophrenia. The deal also offers a read on where investors still see fundable differentiation in CNS: assets that promise efficacy without the movement disorders and metabolic complications associated with traditional dopamine antagonists.
Biopharmaceutical IndustryPfizer Secures Up To $1.5 Billion From Blackstone, Offsetting Berobenatide Development Costs Through 2028
The agreement centers on berobenatide, Pfizer’s monthly GLP-1 receptor agonist acquired in the $9.8 billion Metsera takeover. As Pfizer runs a 10-trial phase 3 program and targets a 2028 launch, the financing offers a way to preserve flexibility ahead of key patent expirations while keeping upside tied to U.S. approval and sales milestones.
Biopharmaceutical IndustryAmgen Posts 70.5% STAR Response For Dazodalibep In Sjögren’s, Setting Up A Novartis Matchup
Amgen’s latest presentation on dazodalibep gives investors a clearer look at how broad the phase 3 benefit may be in systemic Sjögren’s disease. The immediate significance is not only the strength of the placebo-adjusted effect, but how directly the data invite comparison with Novartis as the field moves toward a multi-product market rather than a single-winner launch.
